HDAC4 Reduction: A Novel Therapeutic Strategy to Target Cytoplasmic Huntingtin and Ameliorate Neurodegeneration

PLoS Biology

Volumn 11, Issue 11, 2013, Pages

  Mielcarek, Michal ^a   Landles, Christian ^a   Weiss, Andreas ^b   Bradaia, Amyaouch ^c   Seredenina, Tamara ^d   Inuabasi, Linda ^a   Osborne, Georgina F ^a   Wadel, Kristian ^c   Touller, Chrystelle ^c   Butler, Rachel ^a,i   Robertson, Janette ^a   Franklin, Sophie A ^a   Smith, Donna L ^a   Park, Larry ^e   Marks, Paul A ^f   Wanker, Erich E ^g   Olson, Eric N ^h   Luthi Carter, Ruth ^d   van der Putten, Herman ^b   Beaumont, Vahri ^e   Bates, Gillian P ^a   more..

^a KING'S COLLEGE LONDON   (United Kingdom)

^b NOVARTIS PHARMA AG   (Switzerland)

^c Neuroservice   (France)

^d EPFL   (Switzerland)

^e CHDI MANAGEMENT CHDI FOUNDATION   (United States)

^f MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^g MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^h SOUTHWESTERN UNIVERSITY   (United States)

ⁱ UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; HISTONE DEACETYLASE 4; HUNTINGTIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BDNF GENE; CONTROLLED STUDY; CYTOPLASM; ENZYME INHIBITION; FEMALE; GENETIC TRANSCRIPTION; HUNTINGTON CHOREA; LIFESPAN; MALE; MOTOR COORDINATION; MOUSE; NERVE DEGENERATION; NONHUMAN; PROTEIN AGGREGATION; SYNAPSE;

ANIMALS; BRAIN-DERIVED NEUROTROPHIC FACTOR; CEREBRAL CORTEX; EPIGENESIS, GENETIC; FEMALE; GENE KNOCKDOWN TECHNIQUES; HISTONE DEACETYLASES; HUNTINGTON DISEASE; MALE; MICE; MICE, 129 STRAIN; MICE, INBRED C57BL; MICE, INBRED CBA; MICE, KNOCKOUT; NERVE TISSUE PROTEINS; NEURONS; NUCLEAR PROTEINS; PHENOTYPE; ROTAROD PERFORMANCE TEST; SYNAPTIC TRANSMISSION; TRANSCRIPTION, GENETIC;

EID: 84889031644     PISSN: 15449173     EISSN: 15457885     Source Type: Journal    
DOI: 10.1371/journal.pbio.1001717     Document Type: Article

References (66)

1. Novak MJ, Tabrizi SJ, (2010) Huntington's disease. BMJ 340: c3109.
2. Landles C, Bates GP, (2004) Huntingtin and the molecular pathogenesis of Huntington's disease. Fourth in molecular medicine review series. EMBO Rep 5: 958-963.
3. Cha JH, (2007) Transcriptional signatures in Huntington's disease. Prog Neurobiol 83: 228-248.
4. Butler R, Bates GP, (2006) Histone deacetylase inhibitors as therapeutics for polyglutamine disorders. Nat Rev Neurosci 7: 784-796.
5. Kazantsev AG, Thompson LM, (2008) Therapeutic application of histone deacetylase inhibitors for central nervous system disorders. Nat Rev Drug Discovery 7: 854-868.
6. Haberland M, Montgomery RL, Olson EN, (2009) The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat Rev Genet 10: 32-42.
7. Hockly E, Richon VM, Woodman B, Smith DL, Zhou X, et al. (2003) Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease. Proc Natl Acad Sci U S A 100: 2041-2046.
8. Marks PA, Xu WS, (2009) Histone deacetylase inhibitors: potential in cancer therapy. J Cell Biochem 107: 600-608.
9. Scognamiglio A, Nebbioso A, Manzo F, Valente S, Mai A, et al. (2008) HDAC-class II specific inhibition involves HDAC proteasome-dependent degradation mediated by RANBP2. Biochim Biophys Acta 1783: 2030-2038.
10. Benn CL, Butler R, Mariner L, Nixon J, Moffitt H, et al. (2009) Genetic knock-down of HDAC7 does not ameliorate disease pathogenesis in the R6/2 mouse model of Huntington's disease. PLoS ONE 4 (6) (): e5747 doi:10.1371/journal.pone.0005747.
11. Mielcarek M, Benn CL, Franklin SA, Smith DL, Woodman B, et al. (2011) SAHA decreases HDAC 2 and 4 levels in vivo and improves molecular phenotypes in the R6/2 mouse model of Huntington's disease. Plos ONE 6 (11) (): e27746 doi:10.1371/journal.pone.0027746.
12. Verdin E, Dequiedt F, Kasler HG, (2003) Class II histone deacetylases: versatile regulators. Trends Genet 19: 286-293.
13. Bolger TA, Yao TP, (2005) Intracellular trafficking of histone deacetylase 4 regulates neuronal cell death. J Neurosci 25: 9544-9553.
14. Mao Z, Bonni A, Xia F, Nadal-Vicens M, Greenberg ME, (1999) Neuronal activity-dependent cell survival mediated by transcription factor MEF2. Science 286: 785-790.
15. Guo L, Han A, Bates DL, Cao J, Chen L, (2007) Crystal structure of a conserved N-terminal domain of histone deacetylase 4 reveals functional insights into glutamine-rich domains. Proc Natl Acad Sci U S A 104: 4297-4302.
16. Fiumara F, Fioriti L, Kandel ER, Hendrickson WA, (2010) Essential role of coiled coils for aggregation and activity of Q/N-rich prions and PolyQ proteins. Cell 143: 1121-1135.
17. Mangiarini L, Sathasivam K, Seller M, Cozens B, Harper A, et al. (1996) Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 87: 493-506.
18. Lin CH, Tallaksen-Greene S, Chien WM, Cearley JA, Jackson WS, et al. (2001) Neurological abnormalities in a knock-in mouse model of Huntington's disease. Hum Mol Genet 10: 137-144.
19. Woodman B, Butler R, Landles C, Lupton MK, Tse J, et al. (2007) The Hdh(Q150/Q150) knock-in mouse model of HD and the R6/2 exon 1 model develop comparable and widespread molecular phenotypes. Brain Res Bull 72: 83-97.
20. Sathasivam K, Neueder A, Gipson TA, Landles C, Benjamin AC, et al. (2013) Aberrant splicing of HTT generates the pathogenic exon 1 protein in Huntington disease. Proc Natl Acad Sci U S A 110: 2366-2370.
21. Vega RB, Matsuda K, Oh J, Barbosa AC, Yang XL, et al. (2004) Histone deacetylase 4 controls chondrocyte hypertrophy during skeletogenesis. Cell 119: 555-566.
22. Martin M, Kettmann R, Dequiedt F, (2007) Class IIa histone deacetylases: regulating the regulators. Oncogene 26: 5450-5467.
23. Haberland M, Arnold MA, McAnally J, Phan D, Kim Y, et al. (2007) Regulation of HDAC9 gene expression by MEF2 establishes a negative-feedback loop in the transcriptional circuitry of muscle differentiation. Mol Cell Biol 27: 518-525.
24. Mihaylova MM, Vasquez DS, Ravnskjaer K, Denechaud PD, Yu RT, et al. (2011) Class IIa histone deacetylases are hormone-activated regulators of FOXO and mammalian glucose homeostasis. Cell 145: 607-621.
25. Sathasivam K, Lane A, Legleiter J, Warley A, Woodman B, et al. (2010) Identical oligomeric and fibrillar structures captured from the brains of R6/2 and knock-in mouse models of Huntington's disease. Hum Mol Genet 19: 65-78.
26. Weiss A, Abramowski D, Bibel M, Bodner R, Chopra V, et al. (2009) Single-step detection of mutant huntingtin in animal and human tissues: a bioassay for Huntington's disease. Anal Biochem 395: 8-15.
27. Moumne L, Campbell K, Howland D, Ouyang Y, Bates GP, (2012) Genetic knock-down of HDAC3 does not modify disease-related phenotypes in a mouse model of Huntington's disease. PLoS ONE 7 (2) (): e31080 doi:10.1371/journal.pone.0031080.
28. Bobrowska A, Donmez G, Weiss A, Guarente L, Bates G, (2012) SIRT2 ablation has no effect on tubulin acetylation in brain, cholesterol biosynthesis or the progression of Huntington's disease phenotypes in vivo. PLoS ONE 7 (4) (): e34805 doi:10.1371/journal.pone.0034805.
29. Bobrowska A, Paganetti P, Matthias P, Bates GP, (2011) Hdac6 knock-out increases tubulin acetylation but does not modify disease progression in the R6/2 mouse model of Huntington's disease. PLoS ONE 6 (6) (): e20696 doi:10.1371/journal.pone.0020696.
30. Zourlidou A, Gidalevitz T, Kristiansen M, Landles C, Woodman B, et al. (2007) Hsp27 overexpression in the R6/2 mouse model of Huntington's disease: chronic neurodegeneration does not induce Hsp27 activation. Hum Mol Genet 16: 1078-1090.
31. Hay DG, Sathasivam K, Tobaben S, Stahl B, Marber M, et al. (2004) Progressive decrease in chaperone protein levels in a mouse model of Huntington's disease and induction of stress proteins as a therapeutic approach. Hum Mol Genet 13: 1389-1405.
32. Smith DL, Woodman B, Mahal A, Sathasivam K, Ghazi-Noori S, et al. (2003) Minocycline and doxycycline are not beneficial in a model of Huntington's disease. Ann Neurol 54: 186-196.
33. Hockly E, Tse J, Barker AL, Moolman DL, Beunard JL, et al. (2006) Evaluation of the benzothiazole aggregation inhibitors riluzole and PGL-135 as therapeutics for Huntington's disease. Neurobiol Dis 21: 228-236.
34. Kuhn A, Goldstein DR, Hodges A, Strand AD, Sengstag T, et al. (2007) Mutant huntingtin's effects on striatal gene expression in mice recapitulate changes observed in human Huntington's disease brain and do not differ with mutant huntingtin length or wild-type huntingtin dosage. Hum Mol Genet 16: 1845-1861.
35. Benn CL, Fox H, Bates GP, (2008) Optimisation of region-specific reference gene selection and relative gene expression analysis methods for pre-clinical trials of Huntington's disease. Mol Neurodegener 3: 17.
36. Klapstein GJ, Fisher RS, Zanjani H, Cepeda C, Jokel ES, et al. (2001) Electrophysiological and morphological changes in striatal spiny neurons in R6/2 Huntington's disease transgenic mice. J Neurophys 86: 2667-2677.
37. Cepeda C, Hurst RS, Calvert CR, Hernandez-Echeagaray E, Nguyen OK, et al. (2003) Transient and progressive electrophysiological alterations in the corticostriatal pathway in a mouse model of Huntington's disease. J Neurosci 23: 961-969.
38. Rogers DC, Fisher EM, Brown SD, Peters J, Hunter AJ, et al. (1997) Behavioral and functional analysis of mouse phenotype: SHIRPA, a proposed protocol for comprehensive phenotype assessment. Mamm Genome 8: 711-713.
39. Zhao X, Ito A, Kane CD, Liao TS, Bolger TA, et al. (2001) The modular nature of histone deacetylase HDAC4 confers phosphorylation-dependent intracellular trafficking. J Biol Chem 276: 35042-35048.
40. Miska EA, Langley E, Wolf D, Karlsson C, Pines J, et al. (2001) Differential localization of HDAC4 orchestrates muscle differentiation. Nucleic Acids Res 29: 3439-3447.
41. Darcy MJ, Calvin K, Cavnar K, Ouimet CC, (2010) Regional and subcellular distribution of HDAC4 in mouse brain. J Comp Neurol 518: 722-740.
42. Mielcarek M, Seredenina T, Stokes M, Osborne GF, Landles C, et al. (2013) HDAC4 does not act as a protein deacetylase in the postnatal brain in vivo. PLoS ONE in press.
43. Bottomley MJ, Lo Surdo P, Di Giovine P, Cirillo A, Scarpelli R, et al. (2008) Structural and functional analysis of the human HDAC4 catalytic domain reveals a regulatory structural zinc-binding domain. J Biol Chem 283: 26694-26704.
44. Zuccato C, Tartari M, Crotti A, Goffredo D, Valenza M, et al. (2003) Huntingtin interacts with REST/NRSF to modulate the transcription of NRSE-controlled neuronal genes. Nat Genet 35: 76-83.
45. Li H, Li SH, Cheng AL, Mangiarini L, Bates GP, et al. (1999) Ultrastructural localization and progressive formation of neuropil aggregates in Huntington's disease transgenic mice. Hum Mol Genet 8: 1227-1236.
46. Benn CL, Landles C, Li H, Strand AD, Woodman B, et al. (2005) Contribution of nuclear and extranuclear polyQ to neurological phenotypes in mouse models of Huntington's disease. Hum Mol Genet 14: 3065-3078.
47. Gutekunst CA, Li SH, Yi H, Mulroy JS, Kuemmerle S, et al. (1999) Nuclear and neuropil aggregates in Huntington's disease: relationship to neuropathology. J Neurosci 19: 2522-2534.
48. Kikis EA, Gidalevitz T, Morimoto RI, (2010) Protein homeostasis in models of aging and age-related conformational disease. Adv Exp Med Biol 694: 138-159.
49. Labbadia J, Cunliffe H, Weiss A, Katsyuba E, Sathasivam K, et al. (2011) Altered chromatin architecture underlies progressive impairment of the heat shock response in mouse models of Huntington disease. J Clin Invest 121: 3306-3319.
50. Labbadia J, Novoselov SS, Bett JS, Weiss A, Paganetti P, et al. (2012) Suppression of protein aggregation by chaperone modification of high molecular weight complexes. Brain 135: 1180-1196.
51. Gunawardena S, Goldstein LS, (2005) Polyglutamine diseases and transport problems: deadly traffic jams on neuronal highways. Arch Neurol 62: 46-51.
52. Sassone J, Colciago C, Cislaghi G, Silani V, Ciammola A, (2009) Huntington's disease: the current state of research with peripheral tissues. Exp Neurol 219: 385-397.
53. Moresi V, Williams AH, Meadows E, Flynn JM, Potthoff MJ, et al. (2010) Myogenin and class II HDACs control neurogenic muscle atrophy by inducing E3 ubiquitin ligases. Cell 143: 35-45.
54. Sah DW, Aronin N, (2011) Oligonucleotide therapeutic approaches for Huntington disease. J Clin Invest 121: 500-507.
55. Kordasiewicz HB, Stanek LM, Wancewicz EV, Mazur C, McAlonis MM, et al. (2012) Sustained therapeutic reversal of Huntington's disease by transient repression of huntingtin synthesis. Neuron 74: 1031-1044.
56. Yu D, Pendergraff H, Liu J, Kordasiewicz HB, Cleveland DW, et al. (2012) Single-stranded RNAs use RNAi to potently and allele-selectively inhibit mutant huntingtin expression. Cell 150: 895-908.
57. Takahashi-Fujigasaki J, Fujigasaki H, (2006) Histone deacetylase (HDAC) 4 involvement in both Lewy and Marinesco bodies. Neuropath Appl Neurobiol 32: 562-566.
58. Kilgore M, Miller CA, Fass DM, Hennig KM, Haggarty SJ, et al. (2010) Inhibitors of class 1 histone deacetylases reverse contextual memory deficits in a mouse model of Alzheimer's disease. Neuropsychopharmacol 35: 870-880.
59. Hockly E, Woodman B, Mahal A, Lewis CM, Bates G, (2003) Standardization and statistical approaches to therapeutic trials in the R6/2 mouse. Brain Res Bull 61: 469-479.
60. Wheeler VC, White JK, Gutekunst CA, Vrbanac V, Weaver M, et al. (2000) Long glutamine tracts cause nuclear localization of a novel form of huntingtin in medium spiny striatal neurons in HdhQ92 and HdhQ111 knock- in mice. Hum Mol Genet 9: 503-513.
61. White JK, Auerbach W, Duyao MP, Vonsattel JP, Gusella JF, et al. (1997) Huntingtin is required for neurogenesis and is not impaired by the Huntington's disease CAG expansion. Nat Genet 17: 404-410.
62. Psarros M, Heber S, Sick M, Thoppae G, Harshman K, et al. (2005) RACE: Remote Analysis Computation for gene Expression data. Nucleic Acids Res 33: W638-643.
63. Hochberg Y, Benjamini Y, (1990) More powerful procedures for multiple significance testing. Stat Med 9: 811-818.
64. Davies SW, Sathasivam K, Hobbs C, Doherty P, Mangiarini L, et al. (1999) Detection of polyglutamine aggregation in mouse models. Methods Enzymol 309: 687-701.
65. Weiss A, Klein C, Woodman B, Sathasivam K, Bibel M, et al. (2008) Sensitive biochemical aggregate detection reveals aggregation onset before symptom development in cellular and murine models of Huntington's disease. J Neurochem 104: 846-858.
66. Landles C, Sathasivam K, Weiss A, Woodman B, Moffitt H, et al. (2010) Proteolysis of mutant huntingtin produces an exon 1 fragment that accumulates as an aggregated protein in neuronal nuclei in Huntington disease. J Biol Chem 285: 8808-8823.